BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
BCTX Stock Chart & Stats
$7.28
-$0.02(-3.38%)
At close: 4:00 PM EST
$7.28
-$0.02(-3.38%)
Day’s Range― - ―
52-Week Range$2.93 - $36.00
Previous Close$0.41
Volume996.24K
Average Volume (3M)71.25K
Market Cap
$26.70M
Enterprise Value-$22.79M
Total Cash (Recent Filing)$29.65M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.61
Shares Outstanding8,699,787
10 Day Avg. Volume65,395
30 Day Avg. Volume71,255
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit857.09
Enterprise Value/Ebitda0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero total debt materially lowers financial risk and preserves strategic optionality. For a clinical-stage biotech, this reduces fixed financing costs and bankruptcy risk, enabling management to prioritize R&D and partnership deals over immediate debt servicing for several quarters to years.
Focused Immunotherapy PipelineA clear focus on immunotherapy and a lead clinical asset (Bria-IMT) targeting breast cancer creates a concentrated development pathway. This specialization supports deeper technical expertise, clearer clinical endpoints, and increases attractiveness for strategic partnerships or licensing in a structurally growing oncology sub-sector.
Lean Operating StructureA small employee base suggests a capital-efficient, virtual or outsourced R&D model common in early-stage biotech. Lower fixed payroll enables management to extend runway per financing round, preserves cash for trials, and allows rapid reallocation of resources as programs advance or change priority.
Bears Say
No Revenue And Widening LossesThe absence of revenue means commercialization remains distant and the company is entirely pre-revenue. Materially widening net losses increase the duration and scale of required financing, raising dilution risk and reducing management flexibility to fund pivotal trials without external capital or partners.
High Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow at this scale elevates refinancing risk. Persistent burn forces frequent capital raises or deal-making, which can dilute shareholders and constrain long-term program continuity if markets tighten or partnership options are limited.
Reliance On External FinancingHeavy dependence on external funding makes progress contingent on capital markets and partner interest. In adverse market conditions or with trial setbacks, funding access can tighten, delaying programs or forcing suboptimal transactions that impair long-term value creation for existing shareholders.
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $2.93 and its highest was $36.00 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is $26.70M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 17, 2026 which is in 7 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 10, 2026. The company reported -$2.571 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.571.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 8,699,787 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$2.571 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.911%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-221.75%
Trailing 12-Months
Asset Growth
235.47%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Ownership Overview
37.66% Insiders
4.26% Other Institutional Investors
58.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---